A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

@inproceedings{Neumann2015ANB,
  title={A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice},
  author={Ulf Neumann and Heinrich Rueeger and Rainer Machauer and Siem Jacob Veenstra and Rainer M. Lueoend and Marina Tintelnot-Blomley and Grit Laue and Karen Beltz and Barbara Vogg and Peter Schmid and Wilfried Frieauff and Derya R. Shimshek and Matthias Staufenbiel and Laura Helen Jacobson},
  booktitle={Molecular Neurodegeneration},
  year={2015}
}
Alzheimer’s disease (AD) is the most common form of dementia, the number of affected individuals is rising, with significant impacts for healthcare systems. Current symptomatic treatments delay, but do not halt, disease progression. Genetic evidence points to aggregation and deposition of amyloid-β (Aβ) in the brain being causal for the neurodegeneration and dementia typical of AD. Approaches to target Aβ via inhibition of γ-secretase or passive antibody therapy have not yet resulted in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
21 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…